Uploaded October 2023 | Updated September 2026, 2 weeks ago
Droplet Digital™ PCR (ddPCR™) is a powerful technology that can support many applications, including oncology research and monitoring circulating tumor DNA (ctDNA) to assess minimum residual disease (MRD). Bio-Rad offers hundreds of wet-lab validated mutation and copy number variation (CNV) assays and multiplex mutation screening kits for simultaneous screening of cancer-related mutations in a single reaction. There are also multiple assay design tools to browse for, or design your own Expert Design Assay, all optimized for ddPCR.
Visit bio-rad.com/oncologyhub to see how ddPCR technology is being applied to oncology research, access videos from leading researchers, learn about related ddPCR products, and more: bio-rad.com/en-us/applications-technologies/droplet-digital-pcr-minimal-residual-disease-mrd?ID=2a6a8b3a-f537-59a6-b0f2-16486717e1f8&?WT.mc_id=231005039449
Subscribe to the Bio-Rad channel: youtube.com/user/BioRadLifeScience
We Are Bio-Rad. Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges.
Connect with Bio-Rad Online:
• Website: bio-rad.com/digital-pcr
• LinkedIn: linkedin.com/company/bio-rad
• Facebook: facebook.com/BioRadGenomics
• Twitter: twitter.com/BioRadGenomics
• Instagram: instagram.com/bioradlabs
©2023 Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
#digitalpcr #ddPCR #MRD #oncolocy #cancer #assays #mutation #ctDNA
Music used by permission granted by royalty-free license from Pond5.com
Droplet Digital™ PCR (ddPCR™) is a powerful technology that can support many applications, including oncology research and monitoring circulating tumor DNA (ctDNA) to assess minimum residual disease (MRD). Bio-Rad offers hundreds of wet-lab validated mutation and copy number variation (CNV) assays and multiplex mutation screening kits for simultaneous screening of cancer-related mutations in a single reaction. There are also multiple assay design tools to browse for, or design your own Expert Design Assay, all optimized for ddPCR.
Visit bio-rad.com/oncologyhub to see how ddPCR technology is being applied to oncology research, access videos from leading researchers, learn about related ddPCR products, and more: bio-rad.com/en-us/applications-technologies/droplet-digital-pcr-minimal-residual-disease-mrd?ID=2a6a8b3a-f537-59a6-b0f2-16486717e1f8&?WT.mc_id=231005039449
Subscribe to the Bio-Rad channel: youtube.com/user/BioRadLifeScience
We Are Bio-Rad. Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges.
Connect with Bio-Rad Online:
• Website: bio-rad.com/digital-pcr
• LinkedIn: linkedin.com/company/bio-rad
• Facebook: facebook.com/BioRadGenomics
• Twitter: twitter.com/BioRadGenomics
• Instagram: instagram.com/bioradlabs
©2023 Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
#digitalpcr #ddPCR #MRD #oncolocy #cancer #assays #mutation #ctDNA
Music used by permission granted by royalty-free license from Pond5.com
